A-A-54178
7 June 1990
COMMERCIAL ITEM DESCRIPTION
BROMOCRIPTINE MESYLATE TABLETS, USP
The General Services Administration has authorized the use of this Commercial Item Description.
Salient characteristics.
Shall be Bromocriptine Mesylate Tablets, USP.
Shall be in accordance with the requirements of the USP.
Shall contain the equivalent to 2.5 mg Bromocriptine per tablet, within the applicable assay limits.
All ingredients shall be of pharmaceutical grade.
Each tablet shall be marked/embossed with a product identification code to identify the active ingredient(s), strength, and manufacturer. The materials used in marking/embossing the dosage forms shall be acceptable to the FDA. The actual code used for the product shall be left to the discretion of the supplier.
Workmanship. The tablets shall be free from defects which detract from its appearance or impair its serviceability.
Unit. Bottle (BT). One bottle containing 30 tablets, as specified, constitutes one unit. Bottle shall be supplied with a child-resistant safety closure and shall have a minimum height of 51 mm base to shoulder.
Contractor certification. The contractor shall certify that the product offered meets the salient characteristics of this description and conforms to the producers’ own drawings, specifications, standards, and quality assurance practices. The Government reserves the right to require proof of such conformance prior to first delivery and thereafter as may be otherwise provided for under the provisions of the contract.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business